QOL Medical’s Sucraid Is First To Lose Its REMS
In the brief history of Risk Evaluation and Mitigation Strategies, QOL Medical’s enzyme replacement therapy Sucraid stands out for the unusual reason behind the REMS requirements in the first place, and because it was the first and only product to date to be released from its risk management obligations.
You may also be interested in...
FDA approves Lumizyme for all Pompe disease patients, making it unnecessary to restrict use to a specific age group; Myozyme, produced at a different scale, will remain available.
More than half of a 26-member advisory committee supports eliminating or easing the REMS for GSK’s diabetes drug, but the spilt vote and high-profile of the product’s safety issues suggest that FDA is unlikely to modify Avandia’s risk management.
FDA should take no more than three months deciding whether a Medication Guide can be pulled out of an existing Risk Evaluation and Mitigation Strategy, the Pharmaceutical Research and Manufacturers of America believes.